Navigation Links
SyntheMed, Inc. Announces Stockholder Approval of Planned Merger With Pathfinder, LLC
Date:8/25/2011

RINGWOOD, N.J., Aug. 25, 2011 /PRNewswire/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD; Pink Sheets: SYMD) announced that its stockholders approved the planned merger with Pathfinder, LLC at SyntheMed's special meeting of stockholders held today.  In excess of 99% of the votes cast were voted in favor of the merger.  The proposed merger with Pathfinder was previously announced and is described in detail in SyntheMed's definitive proxy statement filed with the Securities and Exchange Commission on July 26, 2011.  The merger has been approved by Pathfinder's members and is expected to close in the next ten days, subject to satisfaction or waiver of customary and other closing conditions.  

Dr. Richard Franklin, M.D., Ph.D., SyntheMed's Executive Chairman, and CEO and President of Pathfinder, commented, "I am pleased at the support shown by SyntheMed's stockholders.  Pathfinder has great potential, and I look forward to closing the merger and beginning a new direction for the Company."

About Pathfinder

Pathfinder is developing a novel cell-based therapy with the potential to revolutionize the treatment of diabetes, renal disease, myocardial infarction, and other diseases characterized by organ-specific cell damage. Leveraging its internal discovery of Pathfinder Cells ("PCs") and a proprietary means of isolating these cells from surrounding tissue, Pathfinder is pioneering a new field in regenerative medicine. PCs are a newly identified mammalian cell type present in very low quantities in a variety of different organs, including the kidney, liver, pancreas, lymph nodes, myometrium, bone marrow and blood.

Early studies indicate that PCs stimulate regeneration of damaged tissues without the cells themselves being incorporated into the new tissue. The cells are "immune privileged", and their effects are independent of the tissue source of PCs. PCs isolated from both rat and human tissue sources have shown efficacy in animal models of diabetes, cardiac ischemia, and renal reperfusion injury.

For more information please visit: www.pathfindercelltherapy.com.

About SyntheMed

SyntheMed is a biomaterials company focused on the development and commercialization of anti-adhesion and drug delivery products, and other surgical implants. The Company's research and development initiatives encompass a broad range of bioresorbable polymeric compositions which blend both hydrophilic and hydrophobic components. For more information about SyntheMed please visit: www.synthemed.com.

FORWARD LOOKING STATEMENTS

This press release contains forward-looking statements or predictions, including statements regarding the potential closing of the merger and the timing thereof, the characteristics and possible uses of the product candidates of each of Pathfinder and SyntheMed and the potential benefits or value to SyntheMed's stockholders of the merger. Actual results may differ materially from these statements.  For risks associated with the merger and Pathfinder, please see SyntheMed's definitive proxy statement filed with the SEC on July 26, 2011.  For risks associated with SyntheMed's business, please see SyntheMed's Form 10-K filed with the SEC on March 25, 2011.

For more information, please contact:

The Ruth Group
Joshua Drumm (investors) / Victoria Aguiar (media)
(646) 536-7006 / (646) 536-7013
jdrumm@theruthgroup.com / vaguiar@theruthgroup.com

Rick Franklin
Executive Chairmain, SyntheMed, Inc.
President and CEO, Pathfinder Cell Therapy, Inc.
Rick.franklin@pathfindercelltherapy.com


'/>"/>
SOURCE SyntheMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Pathfinder LLC and SyntheMed, Inc. Announce Merger Agreement
2. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
3. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
4. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
5. Anesiva Announces Second Quarter 2008 Financial Results and Update
6. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
7. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
8. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. ThirdBiotech Announces Kemeta as Newest Sponsor
11. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading ... financial results for the fourth quarter and fiscal year of ... Total sales in the fourth quarter of ... 13.6% in USD terms to $77.6 million from $68.3 million ... profit increased by 13.3% to $46.8 million from $41.3 million ...
(Date:2/23/2017)... Financial ... data, unaudited)Three Months Ended December 31,Twelve Months Ended December ... $           300$ ... Net Product Revenue 3539(10)%9498(4)%Kuvan Net ... Revenue  756025%297303(2)%Vimizim Net Product Revenue ...
(Date:2/23/2017)... , Feb. 23, 2017  In Atlanta, it seems ... fashion, and culture intertwine to create an expressive and dynamic ... reflect this energy and contribute to it. ... Hair Fairies seeks to carry on that tradition ... Atlanta salon is the newest of ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... today that in a published evaluation of multiple immunoassay-based threat detection technologies ... of Energy Laboratory, PathSensors’ CANARY® biosensor threat detection technology was found to ...
Breaking Biology Technology:
(Date:2/2/2017)... 2, 2017   TapImmune, Inc. (NASDAQ: ... specializing in the development of innovative peptide and ... cancer and metastatic disease, announced today it has ... of a second clinical lot of TPIV 200, ... alpha. The manufactured vaccine product will be used ...
(Date:2/2/2017)... -- Central to its deep commitment to honor the ... Prize Foundation today announced the laureates of the ... in their respective fields of Life Sciences and ... recognized with the 2017 Japan Prize for original ... the advancement of science and technology, but also ...
(Date:1/31/2017)... , Jan. 31, 2017  Spero Therapeutics, LLC, ... for the treatment of bacterial infections, today announced ... antibacterial candidates from Pro Bono Bio Ltd (PBB) ... of multi-drug resistant forms of Gram-negative bacteria.   The ... Infectives Ltd, a PBB group company. ...
Breaking Biology News(10 mins):